The novel capripoxvirus vector lumpy skin disease virus efficiently boosts modified vaccinia Ankara human immunodeficiency virus responses in rhesus macaques

Journal of General Virology

Volumn 95, Issue , 2014, Pages 2267-2272

  Burgers, Wendy A ^a   Ginbot, Zekarias ^a   Shen, Yen Ju ^a   Chege, Gerald K ^a   Soares, Andreia P ^a   Müller, Tracey L ^a   Bunjun, Rubina ^a   Kiravu, Agano ^a   Munyanduki, Henry ^a   Douglass, Nicola ^a   Williamson, Anna Lise ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CAPRIPOXVIRUS VECTOR; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; MODIFIED VACCINIA ANKARA VECTOR; POXVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; DRUG CARRIER; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CAPRIPOXVIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TOLERABILITY; FOWLPOX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; ORTHOPOXVIRUS; PERIPHERAL BLOOD MONONUCLEAR CELL; RHESUS MONKEY; SINGLE DRUG DOSE; SUCROSE DENSITY GRADIENT CENTRIFUGATION; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; VACCINIA VIRUS; ANIMAL; GENE VECTOR; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METHODOLOGY; TREATMENT OUTCOME; VACCINATION;

AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG CARRIERS; GENETIC VECTORS; HIV-1; LUMPY SKIN DISEASE VIRUS; MACACA MULATTA; TREATMENT OUTCOME; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 84907205642     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.067835-0     Document Type: Article

References (25)

1. Amara, R. R., Nigam, P., Sharma, S., Liu, J. & Bostik, V. (2004). Longlived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol 78, 3811-3816.
2. Aspden, K., Passmore, J. A., Tiedt, F. & Williamson, A. L. (2003). Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector. J Gen Virol 84, 1985-1996.
3. Barouch, D. H. (2010). Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 5, 386-390.
4. Borthwick, N., Ahmed, T., Ondondo, B., Hayes, P., Rose, A., Ebrahimsa, U., Hayton, E. J., Black, A., Bridgeman, A. & other authors (2013). Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 22, 464-475.
5. Burgers, W. A., Shephard, E., Monroe, J. E., Greenhalgh, T., Binder, A., Hurter, E., Van Harmelen, J. H., Williamson, C. & Williamson, A.-L. (2008). Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res Hum Retroviruses 24, 195-206.
6. + T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. J Gen Virol 90, 468-480.
7. Chege, G. K., Burgers, W. A., Stutz, H., Meyers, A., Chapman, R., Kiravu, A., Bunjun, R., Shephard, E. G., Jacobs, W. R. & other authors (2013). Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model. J Virol 87, 5151-5160.
8. de Cassan, S. C. & Draper, S. J. (2013). Recent advances in antibodyinducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert Rev Vaccines 12, 365-378.
9. Garber, D. A., O'Mara, L. A., Gangadhara, S., McQuoid, M., Zhang, X., Zheng, R., Gill, K., Verma, M., Yu, T. & other authors (2012). Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol 86, 12605-12615.
10. García-Arriaza, J., Arnáez, P., Gómez, C. E., Sorzano, C. O. & Esteban, M. (2013). Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways. PLoS ONE 8, e66894.
11. Gómez, C. E., Perdiguero, B., García-Arriaza, J. & Esteban, M. (2012a). Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother 8, 1192-1207.
12. Gómez, C. E., Perdiguero, B., Nájera, J. L., Sorzano, C. O., Jiménez, V., González-Sanz, R. & Esteban, M. (2012b). Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 86, 5026-5038.
13. Gudmundsdotter, L., Nilsson, C., Brave, A., Hejdeman, B., Earl, P., Moss, B., Robb, M., Cox, J., Michael, N. & other authors (2009). Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 27, 4468-4474.
14. Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C. & other authors (2012). Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366, 1275- 1286.
15. Keefer, M. C., Frey, S. E., Elizaga, M., Metch, B., De Rosa, S. C., Barroso, P. F., Tomaras, G., Cardinali, M., Goepfert, P. & Kalichman, A. (2011). A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 29, 1948-1958.
16. Kibler, K. V., Gomez, C. E., Perdiguero, B., Wong, S., Huynh, T., Holechek, S., Arndt, W., Jimenez, V., Gonzalez-Sanz, R. & other authors (2011). Improved NYVAC-based vaccine vectors. PLoS ONE 6, e25674.
17. Kitching, R. P., Hammond, J. M. & Taylor, W. P. (1987). A single vaccine for the control of capripox infection in sheep and goats. Res Vet Sci 42, 53-60.
18. Koff, W. C., Burton, D. R., Johnson, P. R., Walker, B. D., King, C. R., Nabel, G. J., Ahmed, R., Bhan, M. K. & Plotkin, S. A. (2013). Accelerating next-generation vaccine development for global disease prevention. Science 340, 1232910.
19. McElrath, M. J., De Rosa, S. C., Moodie, Z., Dubey, S., Kierstead, L., Janes, H., Defawe, O. D., Carter, D. K., Hural, J. & other authors (2008). HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372, 1894-1905.
20. Penaloza-MacMaster, P., Provine, N. M., Ra, J., Borducchi, E. N., McNally, A., Simmons, N. L., Iampietro, M. J. & Barouch, D. H. (2013). Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J Virol 87, 1373-1384.
21. Perdiguero, B., Gómez, C. E., Di Pilato, M., Sorzano, C. O., Delaloye, J., Roger, T., Calandra, T., Pantaleo, G. & Esteban, M. (2013). Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. PLoS ONE 8, e74831.
22. + T cells following human-, simian-, and chimpanzeederived recombinant adenoviral vector immunization. J Immunol 190, 2720-2735.
23. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M. & other authors (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361, 2209- 2220.
24. Shen, Y. J., Shephard, E., Douglass, N., Johnston, N., Adams, C., Williamson, C. & Williamson, A. L. (2011). A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV). Virol J 8, 265.
25. Shephard, E., Burgers, W. A., Van Harmelen, J. H., Monroe, J. E., Greenhalgh, T., Williamson, C. & Williamson, A. L. (2008). A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. AIDS Res Hum Retroviruses 24, 207-217.